Pediatr. praxi. 2011;12(3):194-198

Use of botulinum toxin type A in treatment of cerebral palsy

MUDr.Miroslava Muchová
Klinika dětské neurologie LF MU a FN Brno

Cerebral palsy is the most common cause of spasticity and movement disorder in children. Untreated spasticity leads to many complications,

and therefore it is necessary to treat spasticity timely and adequately. The treatment of spasticity is complex. Botulinum toxin

A is part of a multidisciplinary approach in the treatment of cerebral palsy. Botulinum toxin A in combination with physiotherapy is

recommended as first-line therapy in the management of spasticity in children. This article provides basic information about spasticity

and its treatment with botulinum toxin A.

Keywords: cerebral palsy, CP, spasticity, spastic movement disorder, botulinum toxin A

Published: July 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Muchová M. Use of botulinum toxin type A in treatment of cerebral palsy. Pediatr. praxi. 2011;12(3):194-198.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Heinen F, Desloovere K, Schroeder AS, et al. The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy. Eur J Paediatr Neurol. 2010; 14(1): 45-66. Go to original source... Go to PubMed...
    2. Odding E, Roebroeck ME, Stam HJ. The epidemiology of cerebral palsy: incidence, impairments and risk factors. Disabil Rehabil. 2006; 2 8(4): 183-191. Go to original source... Go to PubMed...
    3. Kaňovský P, Bareš M, Dufek J, a kol. Spasticita: mechanismy, diagnostika, léčba. Praha: Maxdorf 2004: 410.
    4. Johnson DC, Damiano DL, Abel MF. The evolution of gait in childhood and adolescent cerebral palsy. J Pediatr Orthop 1997; 17: 392-396. Go to original source... Go to PubMed...
    5. Kaňovský P. Botulotoxin a jeho role v léčbě neurologických onemocnění. Neurol. praxi 2001; 1: 42-46.
    6. Ehler E, Štětkářová I. Botulotoxin v léčbě spasticity. Cesk Slov Neurol N 2009; 72/105(4): 317-321.
    7. Koman LA, Money JF, Smith B, et al. Management of cerebral palsy with botulinum A toxin: preliminary investigation. J Pediatr Orthop 1993; 13: 489-495. Go to original source... Go to PubMed...
    8. de Paiva A, Meunier FA, Molgó J, et al. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci USA 1999; 96(6): 3200-3205. Go to original source... Go to PubMed...
    9. Koman LA, Smith BP, Balkrishnan. Spasticity associated with cerebral palsy in children. Guidelines for the use of botulinum A toxin. Pediatr Drugs 2003; 5(1): 11-23. Go to original source... Go to PubMed...
    10. Minks E, Bareš M, Husárová I, Ferencová K. Dlouhodobá léčba spasticity dolních a horních končetin botulotoxinem A u dětí s dětskou mozkovou obrnou: retrospektivní studie. Neurol. pro praxi 2008; 9(5) (Suppl C): 5-22.
    11. Kaňovský P, Bareš M, Severa S, et al. Functional benefit of botulinum toxin (Dysport(R)) in the treatment of dynamic equinus cerebral palsy spasticity: a prospective, multicentre, double-blind, placebo-controlled study. Čes a Slov Neurol Neurochir 2004; 67/100(1): 16-23.
    12. Lukban MB, Rosales RL, Dressler D. Effectiveness of botulinum toxin A for upper and lower limb spasticity in children with cerebral palsy: a summary of evidence. J Neural Transm. 2009; 116(3): 319-331. Go to original source... Go to PubMed...
    13. Ehler E. Současná terapie spasticity se zaměřením na lokální aplikaci botulotoxinu. Neurol. praxi 2001; 3: 128-132.
    14. Kaňovský P, Streitová H, Lněnička J, et al. Indukce změny pohybového vzorce u dětí postižených dětskou mozkovou obrnou navozená současnou léčbou rehabilitační a botulotoxinem A. Čes a Slov Neurol Neurochir 1999; 62/95(4): 203-208.
    15. Kraus J. Spektrum účinku aplikace BTX-A u pacientů se spasticitou. Botulotoxin - včera, dnes a zítra. Liblice, 18.-19. 9. 2009.

    Return to the content


    Pediatrics for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.